The global impact and cost-effectiveness of a melioidosis vaccine.

ABSTRACT: BACKGROUND:Every year, 90,000 people may die from melioidosis. Vaccine candidates have not proceeded past animal studies, partly due to uncertainty around the potential market size. This study aims to estimate the potential impact, cost-effectiveness and market size for melioidosis vaccines. METHODS:Age-structured decision tree models with country-specific inputs were used to estimate net costs and health benefits of vaccination, with health measured in quality-adjusted life years (QALYs). Four target groups of people living in endemic regions were considered: (i) people aged over 45 years with chronic renal disease, (ii) people aged over 45 years with diabetes, (iii) people aged over 45 years with diabetes and/or chronic renal disease, (iv) everyone aged over 45 years. Melioidosis risk wa

SUBMITTER: Luangasanatip N 

PROVIDER: S-EPMC6610909 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature